Oct 12,2023

Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds

Akili released results from a new study examining the ways in which ADHD impacts the U.S. workforce. Akili engaged Wakefield Research to survey 500 employees with ADHD to better understand the experience of working with ADHD, as well as 500 managers to explore how prepared workplaces are to support employees with ADHD. The study found that nearly all employees with ADHD (97%) think they would be capable of accomplishing more if they could better manage their symptoms. 2 in 3 employees (65%) agreed that accomplishing day-to-day work tasks while managing their symptoms poses a moderate to significant challenge. However, managers aren’t sure what to do if an employee tells them they have ADHD

View Analyst & Ambassador Comments
Go to original news
Oct 11,2023

Amwell Partners With Discovery Health in South Africa For Prescribing SilverCloud

Discovery Health, health insurance administrator providing administration and managed care services to more than 3.8 million individuals, has partnered with Amwell to introduce the first-ever digital therapeutic benefits funded by a health insurer in South Africa. As part of the organization’s robust mental healthcare program and benefits package, clinicians are now able to prescribe SilverCloud by Amwell, a clinically validated, evidence-based and affordable digital mental healthcare platform, to members.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Oct 06,2023

Curio Digital Therapeutics: Pivotal Trial for Postpartum Depression Digital Therapeutic Meets Efficacy Endpoints

Curio Digital Therapeutics today announced positive data from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER) trial. SuMMER is a national, randomized, placebo (sham)-controlled pivotal trial evaluating MamaLift Plus for eight weeks in 141 patients (ITT population) randomized in a 2:1 ratio to the MamaLift Plus arm (N = 95) and control (sham digital) arm (N = 46). The SuMMER trial met its primary endpoint, a ?4-point improvement in Edinburgh Postnatal Depression Scale (EPDS) score. Preliminary results indicate that approximately 83% of participants in the intervention arm achieved a 4-point improvement in EPDS score, compared to only 22% in the control arm. Approximately 82% of patients in the intervention arm achieved an EPDS reduction to <13, compared to only 30% in the control arm.

CLINICAL STUDY

#cbt

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 28,2023 TOP STORY

GAIA's New Depression Therapy for MS Shows Significant Results

In the study published in Lancet Digital Health, GAIA’s (digital) depression therapy “amiria” was able to show that it can significantly reduce depression symptoms and that the positive therapy effects were even detectable up to 1 year after the end of therapy. This parallel-group, randomised, controlled, phase 3 trial of an iCBT programme to reduce depressive symptoms in patients with multiple sclerosis was carried out at five academic centres with large outpatient care units in Germany and the USA. The predefined primary endpoint, which was analysed in the intention-to-treat population, was severity of depressive symptoms as measured by the Beck Depression Inventory-II (BDI-II) at week 12 after randomisation. 279 participants were enrolled, of whom 101 were allocated to receive stand-alone iCBT, 85 to receive guided iCBT, and 93 to the control condition. he dropout rate at week 12 was 18% (50 participants). Both versions of the iCBT programme significantly reduced depressive symptoms compared with the control group. The approval of amiria for the treatment of depression in MS patients in Germany (BfArM) is currently being prepared.

CLINICAL STUDY

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Aug 26,2023

Chula Vista Veterans Home to be First Recipients of Immersive VR Glasses Through BVL Grant

MyndVR, the leading provider of VR-based, digital therapeutic experiences for the aging population, has announced the deployment of virtual reality glasses to all eight Veterans Homes of California. The deployment of MyndVR technology is made possible by a grant from BVL (Bowlers to Veterans Link), a 501c3 charity dedicated to funding recreation therapy programs that address the emotional and physical needs of veteran and active-duty military personnel. The BVL grant was created to help deploy MyndVR technology through the innovative HTC Vive immersive glasses, to 50 state veterans homes across the United States. The California Department of Veteran Affairs (CalVet) is the third state veterans home group selected to receive the immersive technology. MyndVR distributes headsets to all eight CalVet locations statewide via $250,000 grant.

COLLABORATION PARTNERSHIP

#institution

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Sep 27,2023 TOP STORY

Dario Publishes New Research Demonstrating Clinically Significant Reductions in Depression Through its Digital Behavioral Health Programs

DarioHealth announced new research published in the Journal of Medical Internet Research (JMIR) demonstrating the impact of coaching and breathing exercises as part of the Dario digital behavioral health program alongside coaching and breathing exercises for members living with depression or anxiety. The study ''Specifying the Efficacy of Digital Therapeutic Tools for Depression and Anxiety: Retrospective, 2-Cohort, Real-World Analysis'' analyzed the data of participants in two cohorts engaged in Dario's digital self-guided programs who started at a moderate or high level of depression or anxiety. These study participants engaged in Dario's digital programs alongside the use of a coach or digitally-delivered breathing exercises over the course of 16 weeks to understand the impact of these support mechanisms. The analysis revealed a significant decrease in depression and anxiety symptoms during the first six weeks which was maintained throughout the rest of the 16 weeks program. 63% of members using Dario to manage depression experienced an overall improvement in symptoms, and the use of coaching support significantly moderated symptoms in the first six weeks.

CLINICAL STUDY

#cbt

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 21,2023

Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD

Akili today announced that EndeavorOTC, the mobile video game treatment to improve attention and focus in adults with ADHD, is now available on Google Play. Out of the estimated 11 million adults living with ADHD in the United States, approximately 40% are Android users, so the Company believes this release represents a crucial step in offering an accessible non-drug treatment option to adults with ADHD. Last month, the FDA and the DEA issued a joint statement on the ongoing nationwide shortage of stimulants for the treatment of conditions such as ADHD, noting the FDA’s support of non-drug treatment options including Akili’s EndeavorRx product. The Android release follows EndeavorOTC’s release on the Apple iOS App Store in June 2023. EndeavorOTC now features Akili’s recently released Focus Score, a new metric for users. Focus Score provides a measurement of how quickly and accurately patients can complete a task despite distractions during gameplay.

PRODUCT

#mobile app

#gamification

View Analyst & Ambassador Comments
Go to original news
Sep 20,2023

OSF HEALTHCARE REDUCES RATES OF DEPRESSION AND ANXIETY BY OVER 50% USING THE AMWELL® PLATFORM

OSF HealthCare, an integrated health system with more than 150 locations in Illinois and Michigan, has achieved significant clinical outcome improvements across its behavioral health patient community by leveraging the Amwell Converge™ platform. Results include: 58% clinical improvement for patients with moderate behavioral health conditions; 53% improvement in patient depression screening scores; 50% improvement in patient anxiety screening scores; 94% patient satisfaction rate with the SilverCloud® by Amwell platform. In 2018, OSF HealthCare implemented SilverCloud by Amwell, a global, digital mental health platform that provides 24/7 access to digital services for people who have mild to moderate symptoms of stress, depression and anxiety. The health system offered the digital program to anyone in its service area without the need for a referral or to be an existing OSF patient, and saw steady and positive adoption rates and a 300% increase in enrollments throughout the pandemic. Today, the program has more than 8,500 patient users.

COLLABORATION PARTNERSHIP

#institution

#virtual care

View Analyst & Ambassador Comments
Go to original news
Sep 13,2023 TOP STORY

Akili Announces Business Transformation, Focusing on Non-prescription Model

Akili, Inc. today announced its strategic plan to transition from a prescription to a non-prescription business model. The company plans to pursue regulatory approval for over-the-counter labeling of its products. Akili’s focus on a consumer-led subscription model will reduce reliance on payers and enable the company to grow the business in line with the increasing demand for non-drug cognitive treatments. Akili believes that this non-prescription model will enable the company to increase consumer access and generate revenues that will support gross margins between 60 and 70 percent by late 2025. Eddie Martucci, CEO and co-founder of Akili, continued: “We have seen the non-prescription model play out with EndeavorOTC, which we released in June as a treatment for adults with ADHD. In its first three months on the market, consumer demand, engagement, and retention all surpassed our expectations. We believe that our shift to a consumer-led model across our business will maximize our reach in the ADHD patient community and allow us to potentially expand into other large markets, without many of the high cost centers of a prescription model.” The Company shared that EndeavorOTC in its first three months in the market generated 125,971 first time app downloads, $81.88 average revenue per users who paid in the period (ARPU), and 51% retention of monthly subscribers after 1 month and 67% retention after 2 months.

PRODUCT

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 28,2023

New Woebot Health Study Highlights AI's Ability to Address Equity and Accessibility Gaps in Mental Health Care

Woebot Health today announced the results from a new study of Woebot for Adults (previously Woebot-LIFE), a digital mental health intervention that provides in-the-moment support to people experiencing symptoms of anxiety and depression. The study, in which 256 adults received an 8-week intervention, was designed to assess changes in depression and anxiety symptoms, stress, resilience, burnout, levels of engagement and therapeutic working alliance, as well as access and barriers to care. Key study findings showed that participants with baseline clinical levels of depressive or anxiety symptoms experienced significant declines in self-reported symptoms. Woebot for Adults is a non-prescription medical device under FDA enforcement discretion; it is not evaluated, cleared or approved by FDA. Robinson added the study will periodically relaunch to collect new data and new insights as part of the company’s “Science in the Loop” approach to product development.

CLINICAL STUDY

#chatbot

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH